Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Understanding the relationship between Xylella fastidiosa and the meadow spittlebug Philaenus spumarius for a sustainable bacterial-mediated diseases control (XYL-SPIT)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Global Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Environment and Geosciences
Countries involved: Spain,United States
Call: Individual Fellowships (H2020-MSCA-IF-2018, 2018)
Start date: 2020-01-16
End date: 2023-11-01
Duration (months): 36.0
Total project cost (EUR): 245732.16
EU funding (EUR): 245732.16
Participants: 2
Project status: CLOSED

Research on sustainable containment strategies of diseases caused by the vector-borne bacterium Xylella fastidiosa is hampered by the lack of knowledge on key elements of vector-host-bacterium intimate interaction. Moreover, available data on this three-way relationship come from studies carried out with sharpshooters, the main American bacterial vectors. On the other side, nothing is known on the insect family who likely plays the major role in bacterium epidemiology in Europe, i.e. spittlebugs, to which Philaenus spumarius, the main vector of X. fastidiosa to olive in South Italy, belongs to. The main objective of this project is to thoroughly characterize P. spumarius-X. fastidiosa relationship and transmission dynamics through a multidisciplinary approach, combining real-time tracking of insect probing behavior, classical transmission tests and microscopy. First, we are going to characterize the spittlebug acquisition/inoculation behaviors of the bacterium on different host plant/bacterium strain combinations. Once these behaviors have been characterized, we will determine the sites within spittlebug foregut where bacterial cells are retained suddenly after acquisition, and from where the cells are detached and delivered to the host plant during inoculation. Finally, we will focus on P. spumarius behavior on, and X. fastidiosa transmission dynamic to, olive varieties found to be tolerant to the bacterium. The results of the present project will represent an essential step toward the set-up of a sustainable bacterium-mediated diseases containment strategy. This fellowship represents a unique opportunity for the applicant. The experience gained from this three-year multidisciplinary project will make Daniele Cornara a serious candidate for an academic position throughout Europe, beside an important resource for Europe considering the threat posed by the relentless spread of X. fastidiosa throughout the Continent.

Keywords: spittlebug,bacterium,olive,sustainable control
New drug for the treatment of rheumatoid arthritis (RheumArth)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: Denmark
Call: SME instrument (H2020-SMEInst-2018-2020-1, 2018)
Start date: 2018-05-01
End date: 2018-09-30
Duration (months): 5.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

Rheumatoid arthritis (RA) is a chronic autoimmune disorder causing inflammation and permanent damage in joints and surrounding tissues - leading to severe disability, decreased quality of life, and reduced life expectancy. The disease affects more than 6 million people with annual costs amounting to €45billion in the Europe (EU) alone. There is a wide range of drug therapies for RA, mobilizing a variety of anti-inflammatory and immune modulating effects. However, a significant proportion (30%) of the patients do not respond to current treatments, efficacy is often reduced over time and the incidence of side effects is high and can be severe and life threatening. AP1189 is new chemically-synthesized small molecule drug for the treatment of Rheumatoid arthritis (RA). Through specific activation of the patients’ self-anti-inflammatory mechanisms, our first drug candidate renders unprecedent combination of safety, effectiveness and patient compliance, without the side effects associated with current therapies. The clinical validation of our drug for RA - 1st indication (foreseen for the Innovation Project) - will not only open a large market within this therapeutic area, as it will allow Synact to set a market foothold in the chronic inflammatory disease market, supporting the company´s medium term strategic positioning as an unique provider of a new generation of anti-inflammatory drugs. AP1189 clinical validation is on-going with current Phase I clinical trials showing promising preliminary results – safety and tolerance was proved in healthy human volunteers. Next step in the development will be a Phase IIa Proof-Of-Concept (POC) trail to validate our drug´s efficacy profile in RA patients. In this context, the present Phase 1 will be of utmost importance to validate AP1189´s market position and potential in RA and prepare the large clinical validation aimed for in the ensuing SME Instrument Phase II project.

Keywords: chronic inflammatory disease,rheumatoid arthritis,oral agents,clinical trials
AUTOMATED VALUATION FOR PROPERTY INVESTMENT ANALYSIS (XQ AVM)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: Finland
Call: SME instrument (H2020-SMEInst-2018-2020-1, 2019)
Start date: 2019-07-01
End date: 2019-12-31
Duration (months): 6.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

Current practices in financial valuation of commercial properties are based on manual processes. Automation is needed to help companies on everyday financial modelling, collaboration, valuation and reporting tasks. Exquance Sofware Oy offers a game changing solution: Software platform with a unique calculation engine and breakthrough innovative Exquance Automated Valuation Model (XQ AVM) calculates property valuations without human intervention. The innovation creates 95% costs savingscompared to current costs of valuation of any building. Delivery time is only some minutes compared to several hours with current methods. Immediate gains in operative efficiency, and enhancing the quality of financial modelling, and internal and external reporting, are reached. Competitive niche-oriented solutions are based on normalised data and not scalable. The first phase solutions are targeted to professional players in the €8,000M software market of the real estate investment industry, the solution is scalable to all investment markets globally. The business model is SaaS, transaction-based per purchased appraisal report. The shareable content makes it possible to reach clients' customers and partner companies and opens up the viral, network based user acquisition channel. Exquance Software Oy develops innovative solutions for commercial property valuation and investment management aiming to be the leading vendor of industrial, financial modelling and AVM solutions in the EU and Asia. Dedicated team of 26 professionals in software development, business management with an in-depth understanding of real estate investment industry, and international sales. The company has realised €1M revenue to date and €600k equity investments. Company has strong client base; 13 effective client agreements with major industry players, and 300 clients have expressed their interest in the XQ AVM innovation. The impacts will be reaching 10 000 clients and creating €40M revenue and 400 jobs by 2023.

Keywords: data markets,business,valuation,artificial intelligence,sevices,platforms,advanced analytics,real,estate,property valuation,saas,software development
Systematic Genetic Code Reprogramming (SGCR)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Advanced grants
Action type: ERC actions
Panel: Biotechnology and Biosystems Engineering
Panel description: Biotechnology using all organisms, biotechnology for environment and food applications, applied plant and animal sciences, bioengineering and synthetic biology, biomass and biofuels, biohazards
Countries involved: United Kingdom
Call: ERC Advanced Grant (ERC-2014-ADG, 2014)
Start date: 2016-01-01
End date: 2022-06-30
Duration (months): 78.0
Total project cost (EUR): 2475344.0
EU funding (EUR): 2475344.0
Participants: 2
Project status: CLOSED

We will build an orthogonal translation system for the encoded synthesis of unnatural polymers in cells. The steps towards this goal are each significant and substantial and, importantly, our solutions for each step are both scalable and modular with those for other steps in the process. In the first step we create a scalable and modular route to multiple new aminoacyl-tRNA synthetase/tRNA pairs that are orthogonal to each other and to endogenous synthetases and tRNAs. In a second step we engineer a cell for orthogonal translation to enable each orthogonal tRNA to quantitatively and efficiently decode a distinct quadruplet codon. In a third step we invent a modular and scalable route to program the active sites of mutually orthogonal synthetases to uniquely recognize distinct unnatural building blocks. The modular combination of the advances in each step enables the conversion of genetic code expansion with one or two unnatural amino acids into a scalable technology for genetic code reprogramming, facilitating the encoded synthesis of unnatural polymers using a synthetic genetic code with more encoded monomers than the natural genetic code.

Keywords: protein translation
A long-lasting non-migrating hydrogel for relieving chronic pain (HydroLieve)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Proof of concept grants
Action type: ERC actions
Panel: Prevention, Diagnosis and Treatment of Human Diseases
Panel description: Medical technologies and tools for prevention, diagnosis and treatment of human diseases, therapeutic approaches and interventions, pharmacology, preventative medicine, epidemiology and public health, digital medicine
Countries involved: Ireland
Call: ERC Proof of Concept Grant (ERC-2018-PoC, 2018)
Start date: 2018-08-01
End date: 2020-12-31
Duration (months): 29.0
Total project cost (EUR): 149953.75
EU funding (EUR): 149953.75
Participants: 1
Project status: CLOSED

Chronic Neuropathic Pain (NeP) is an enormous problem globally. Estimates predicate that 20% of adults suffer from pain world-wide and 10% are newly diagnosed with chronic pain annually1. According to the EuroPain Innovative Medicines Initiative (IMI)2, one in five adults in Europe suffers from chronic pain. One type of Neuropathic Pain that is particularly detrimental to patients quality of life is Trigeminal Neuralgia (TN). The trigeminal nerve is responsible for facial sensory function, and trauma to this nerve can result in sudden, severe, stabbing and recurrent episodes of pain. Patients with TN experience a prolonged debilitating condition, where the pain is often described as one of the most painful conditions in medicine. TN is infamously called the “suicide disease” as there have been numerous suicide reports associated with the condition. Epidemiologists estimated the prevalence of chronic TN pain is also large at 7%3, which amounts to 36 million Europeans. Similarly, in the US, the American Association of Neurological Surgeons report that 150,000 people are diagnosed with TN every year with a prevalence of chronic TN impacting 1.7 % of population 4. Therefore in this proposal, we describe the development of a long-lasting and drug-free treatment for chronic Trigeminal Neuralgia.

Keywords: hydrogel,medical devices,pain management
a disruptive implantable neurostimulator for the treatment of epilepsy (NAOS)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: Belgium
Call: SME instrument (H2020-SMEInst-2018-2020-1, 2019)
Start date: 2019-07-01
End date: 2019-11-30
Duration (months): 5.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

The objective of this innovation project is to develop a disruptive implantable neurostimulator for the treatment of epilepsy with the goal to place it on the market by 2021. Neurostimulation is a $4.7 billion market and one of the fastest-growing areas of medicine, that has been approved for the treatment of several neurological disorders. Among these, epilepsy is the most frequent nervous system disease. Of the 50 million people suffering from epilepsy, with 3.7 million in Europe, approximately one third of them are resistant to medication but respond well to the neurostimulation. Neurostimulators are small implanted devices stimulating nerves or brain tissue. The innovative aspects of the project are based on a Synergia Medical’s patented concept and consists in replacing wires by optical fibres. The innovation will improve the traditional therapy and brings the main following competitive advantages: - it renders the neurostimulator compatible with magnetic resonance imaging (MRI) diagnosis - it provides a highly tunable stimulation and ultra low power consumption - it improves safety due to electrical isolation and allow for a smaller size implant The main objective of this feasibility study is to complete the business plan by: - completing a market study and refining specifications of the neurostimulator with key opinion leaders in the field of epilepsy; - manufacturing prototypes of neurostimulators to validate stimulation capabilities, low power consumption, compactness, optical chain efficiency and estimate production costs; - refining the development and production planning, including budget and human resources, based on cost estimates and test results; - finalizing the selection of subcontractors involved in the production chain; - filing additional patents and realizing a complete FTO.

Keywords: epilepsy,neurostimulation,implantable device
Open Innovation Ecosystem for Sustainable Nano-functionalized Flexible Plastic and Paper Surfaces and Membranes (FlexFunction2Sustain)

Framework: Horizon 2020 — Industrial Leadership
Programme: Nanotechnologies, Advanced Materials, Advanced Manufacturing and Processing, and Biotechnology
Theme: Advanced materials
Action type: Innovation actions
Countries involved: Austria,Germany,Germany,Germany,Germany,Austria,Italy,Germany,Greece,Switzerland,Belgium,France,France,Czechia,Portugal,Portugal
Call: Open Innovation Test Beds for nano-enabled surfaces and membranes (IA) (H2020-NMBP-HUBS-2019, 2019)
Start date: 2020-04-01
End date: 2024-03-31
Duration (months): 48.0
Total project cost (EUR): 16100872.31
EU funding (EUR): 14231400.0
Participants: 24
Project status: SIGNED

Plastic and paper based flexible materials and films are used in a wide range of daily life products e.g. in packaging, furniture surface finish, consumer electronic devices, architecture or in car windows. Applications represent well established multi-billion Euro markets. Key Enabling Technologies for a majority of these applications are based on nano-enabled functionalization of the surfaces. Today, Industry faces game-changing, critical challenges for societal acceptance and economic competitiveness: (1) Overcome plastic waste pollution and follow the European Strategy for Plastics in a Circular Economy towards the development of sustainable materials; (2) Keep pace with digitisation and get products ready for integration of smart systems and intelligent products. FlexFunction2Sustain will be the first European Initiative to support the Industry in overcoming these challenges through a sustainable Open Innovation Ecosystem. FlexFunction2Sustain will develop dedicated services to boost innovation for nano-functionalised flexible plastic and paper surfaces and membranes and offer those services to users, in particular SMEs, in all 28 EU countries through an independent single entry point (SEP) legal entity with multiple regional front offices. FlexFunction2Sustain connects complementary pilot lines to a set of 9 connected lab-2-fab facilities covering all major nano-surface processing techniques for (flexible) plastic and paper surfaces and membranes. The facilities and novel surface functionality will be demonstrated in six relevant industrial application scenarios. 20 pre-commercial pilot cases will demonstrate the Services of the FlexFunction2Sustain OITB The FlexFunction2Sustain OITB is prepared to support the client at any point in the innovation chain from TRL4 to TRL7 with and integrated technological, business development and verification/pre-certification service portfolio that helps the client to progress quickly through the innovation chain.

Keywords: nano functionalized plastic surfaces,paper,thin film nano materials,sustainability,recycling,packaging,permeation barrier,structural electronics,bio degradability,optical films
Innovative Low-Mass Tanks for a Low-Cost, Low-Carbon European Micro-Launch Vehicle (PRIME)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: Germany,Denmark,United Kingdom
Call: SME instrument (H2020-SMEInst-2018-2020-2, 2019)
Start date: 2019-07-01
End date: 2022-06-30
Duration (months): 36.0
Total project cost (EUR): 3576559.7
EU funding (EUR): 2497937.4
Participants: 3
Project status: CLOSED

Small satellites (smallsats) are playing an increasingly significant role in space. Smallsats currently fly to space via ridesharing – taking spare capacity on a large launcher. Rideshare has numerous issues, including lack of availability, severe launch delays, and unsuitable orbits. Orbex is developing an EU-based orbital micro-launch vehicle with a uniquely innovative advantage that eliminates the issues of rideshare and mitigates the cost of a dedicated launch for smallsat operators. The vehicle exploits the properties of dual-cryogenic propellants to create an innovative, lightweight, low-cost tanking arrangement that reduces the inert mass of the launch vehicle by as much at 30% over traditional designs, and enable the world’s first environmentally-friendly rocket fuel strategy, with a 90% reduction in environmental impact. The small satellite launch market is well established and growing rapidly. The market for smallsat launch services is projected to grow US$2.52B p.a, by 2022, a CAGR 23.2%. The benefits of developing this tanking system for a European micro-launch vehicle include:- • Lowering cost of space access, including logistics/integration • Reduced delay in time-to-market • Enabling faster revenue generation for smallsat business models Orbex staff have designed & realized a prototype tank, and subsequently drafted patents for the technology. The tank was instrumented, hydrostatically pressure-tested and then used to prove the concept in cryogenic conditions. The objective of this SME Instrument Phase 2 project is to build on a prior SME Instrument Phase 1 feasibility study of the materials, suppliers and production processes required to implement this novel fuel tank concept using European materials and techniques at full scale. This Phase 2 project allow a European company to compete for this large, global market with significant, sustainable cost and operational advantages over global competitors.

Keywords: space access,micro launcher,low mass,low carbon
Cerebral Organoids: Using stem cell derived 3D cultures to understand human brain development and neurological disorders (MiniBrain)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Advanced grants
Action type: ERC actions
Panel: Neuroscience and Disorders of the Nervous System
Panel description: Nervous system development, homeostasis and ageing, nervous system function and dysfunction, systems neuroscience and modelling, biological basis of cognitive processes and of behaviour, neurological and mental disorders
Countries involved: Austria
Call: ERC Advanced Grant (ERC-2015-AdG, 2015)
Start date: 2017-01-01
End date: 2021-12-31
Duration (months): 60.0
Total project cost (EUR): 2800000.0
EU funding (EUR): 2800000.0
Participants: 1
Project status: CLOSED

Most of our knowledge on human development and physiology is derived from experiments done in animal models. While these experiments have led to a comprehensive understanding of the principles of neurogenesis, animal models often fall short of modelling many of the most common neurological disorders. Recent experiments have revealed characteristic striking differences in brain development between rodents and primates and may provide an explanation for this problem. The goal of this proposal is to use three dimensional organoid cultures derived from pluripotent human stem cells to reveal the human specific aspects of brain development and to analyse neurological disease mechanisms directly in human tissue. We have recently developed a 3D culture method allowing us to recapitulate human brain development during the first trimester of embryogenesis. Using this method, we will define the human specific brain patterning events in order to develop a culture system that can recapitulate essentially any part of the brain. Using a unique combination of cell type specific markers and mutagenic viruses, we will define the transcriptional networks defining specific neuronal subtypes. This will allow us to perform loss-of function genetics in human tissue to define transcription factors necessary for development of individual neuronal subtypes on a genome-wide level. Finally, we will apply the genome wide screening technology to human neurological disorders like microcephaly or schizophrenia to identify factors that can rescue disease phenotypes. This research proposal will provide fundamental insights into the cellular and molecular mechanisms specifying various neuronal subclasses in the human brain and establish technology that can be applied to a variety of cell types and brain regions. The proposed experiments have the potential to yield fundamental insights into human neurological disease mechanisms that can currently not be derived from animal models.

Keywords: tissue culture models,organoids